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In a recent paper in Cell, Oricchio et al. identify EPHA7 as a tumor suppressor gene residing in the 6q-
deleted region in follicular lymphoma. A truncated EPHA7TR isoform is secreted by normal B cells, inhibits
EPHA2 signaling, and, as a secreted tumor suppressor protein, has potential as a targeted therapeutic poly-
peptide.Overexpression of BCL2 resulting from
its juxtaposition to the immunoglobulin
heavy-chain enhancer due to the
t(14;18)(q32;q21) chromosomal translo-
cation occurs in nearly 90% of follicular
lymphomas (FLs) and is generally re-
garded as the primary event in the patho-
genesis of this disease (Yunis et al., 1987).
However, several lines of evidence sup-
port the notion that t(14;18) is not suffi-
cient to initiate tumorigenesis in its own
right. Importantly, Bcl2 transgenic mice
have a low penetrance and long latency
of FL development, suggesting that addi-
tional molecular events are required for
transformation (Egle et al., 2004). Rather
alarmingly, minor B cell clones harboring
t(14;18) are detectable in the peripheral
blood of over 50% of healthy individuals.
When these clones are followed over
time, some are found to persist and even
expand during the ensuing years, yet the
incidence of FL remains comparatively
low with only two to three cases per
100,000 persons diagnosed each year
(Roulland et al., 2006).
Relatively little is known about the
precise molecular events that lead to the
malignant transformation of BCL2-over-
expressing B cell clones to FL. Some
clues have been provided by array com-
parative genomic hybridization (aCGH),
which has demonstrated that both chro-
mosomal deletions and gains are frequent
in FL (Cheung et al., 2009). The two most
common chromosomal lesions found in
FL are 11 Mb deletions of chromosome
1p36 (25% of cases) and large deletions
of chromosome 6q (10%–15% of cases),both of which are associated with inferior
outcomes and progression to high-grade
lymphoma (Cheung et al., 2009). Among
the many hundreds of genes that reside
in these genetic loci, the most compelling
case for a gene with tumor-suppressor
function has been made for TNFAIP3 at
6q23.3. TNFAIP3 encodes a zinc finger
protein that negatively regulates NF-kB
and whose deletion constitutively acti-
vates this pathway (Wertz et al., 2004).
However, a significant proportion of
patients with FL have 6q deletions that
do not include the TNFAIP3 locus, sug-
gesting the presence of other tumor-
suppressor genes in this region.
In an elegant paper recently published
in Cell, Oricchio et al. (2011) find that
Ephrin receptor A7 (EPHA7) is a novel
tumor-suppressor located in a common
region of deletion (CRD) of chromosomal
band 6q16 in FL (Oricchio et al., 2011).
By performing and analyzing aCGH
data from FL samples, the authors identi-
fied highly heterogeneous and complex
6q11-27 deletions in 23% of cases. They
mapped 11 hemizygous CRDs, which
varied in size from 5 kb to 27 Mb, encom-
passing up to 78 genes each.
To search for tumor suppressors,
Oricchio and colleagues used a pooled
shRNA library specific for genes within
the different 6q CRDs and tested them
for their ability to rescue Bcl2-overex-
pressing pro-B lymphocytes from growth
factor withdrawal in vitro. Two of their
top hits were Tnfaip3, supporting pre-
vious work that implicated this gene as
a bona fide tumor suppressor in B cellCancer Cell 20, Nnon-Hodgkin lymphoma, and EphA7, a
novel candidate tumor suppressor gene.
EPHA7 protein was readily detectable in
normal germinal center B cells by immu-
nohistochemistry, but was absent in
nearly three quarters of a large series of
primary FL cases, which was often found
to be due to the deletion of one allele
and suppression of the other by aberrant
methylation of the EPHA7 promoter.
The pathobiological significance of
EPHA7 became apparent when Oricchio
et al. tested the in vivo consequence of
EphA7 knockdown on the development
of FL in a Bcl2 transgenic mouse model.
Transduction of hematopoietic stem
cells from these animals with EphA7
shRNAs, followed by their transplantation
into irradiated recipients, led to marked
acceleration of lymphoma onset as well
as an increase in disease penetrance.
Interestingly, lymphomas in the EphA7
knockdown animals maintained the
typical features of FL but expressed
higher levels of the proliferation marker
Ki67, which might explain the clinical
association between 6q deletion and
transformation to a more aggressive
phenotype seen in patients.
With 14 members, Ephrin receptors
form the largest and possibly most com-
plex family of signaling receptor tyrosine
kinases in mammals and have diverse
functions in embryonic development
and angiogenesis (Pasquale, 2010). They
have both oncogenic and tumor sup-
pressor roles, and somatic mutations
have been described in EPHA7 in lung
cancer (Ding et al., 2008). The Ephrinovember 15, 2011 ª2011 Elsevier Inc. 559
Figure 1. A Proposed Mechanism of EPHA7/EPHA2 Signaling in
Normal and Malignant B Cells
(A) Normal B cells express only a truncated form of EPHA7, termed EPHA7TR,
that lacks the transmembrane domain and all intracellular domains and is
secreted from B cells. EPHA7TR binds the homologous EPHA2 receptor and
acts as a dominant-negative inhibitor of EPHA2 receptor dimerization and acti-
vation.
(B) In follicular lymphoma, loss of EPHA7TR expression through genetic dele-
tion and/or promoter hypermethylation allows EPHA2 to undergo homodime-
rization, presumably after binding one or more of the Ephrin ligands. This leads
to phosphorylation of several intracellular sites (yellow circles), activating
downstream signaling proteins, including STAT3, SRC, and ERK. Lymphoma
cells become dependent on these oncogenic signals.
(C) An anti-CD20-EPHA7FC fusion antibody is able to bind both CD20 and
EPHA2. Apoptosis is initiated by both direct CD20 binding and via the inhibition
of ERK and SRC signaling as a consequence of the EPHA7FC/EPHA2 interac-
tion. The figure depicts that the fusion antibody bridges neighboring cells;
however, the steric orientation of binding of this antibody to both receptors
is unknown. Therefore, the antibody may also bind to both receptors on the
same cell.
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vated primarily through cell-
to-cell contact with their
membrane-bound ligands,
which not only drive a
‘‘forward’’ kinase signal, but
also a ‘‘reverse’’ SRC kinase
signal in the Ephrin-express-
ing cell (Pasquale, 2010). The
complexity of the signaling
cascade comes not only from
this bidirectional signaling,
but also from the promiscuity
of ligand-receptor interac-
tions and the impact of se-
creted forms of ligand that
can be generated by alterna-
tive splicing. As an example
of the latter, a truncated
form of the EPHA7 receptor
(EPHA7TR) that lacks the intra-
cellular kinase domain has
been identified in neuronal
development where it binds
to and inhibits the full-length
EPHA7 isoform, leading to
closure of the neural tube
(Holmberg et al., 2000).
Oricchio and colleagues
have uncovered an intriguing
tumor suppressor function
for the EPHA7TR isoform in
lymphoma. Normally, germi-
nal center B cells express
only the EPHA7TR isoform,
which is secreted, and in the
absence of a full-length
EPHA7 receptor, heterodi-
merizes with the EPHA2
receptor and inhibits its
homodimerization in a domi-
nant-negative fashion (Fig-
ure 1A). This maintains the
EPHA2 receptor in the un-
phosphorylated and thus in-
active state. In FL, when
EPHA7TR is epigenetically
silenced or deleted, EPHA2
is able to homodimerize and
activate oncogenic signaling
through ERK, STAT3, and
SRC (Figure 1B).
The unique role of the
EPHA7TR isoform as a se-
creted tumor suppressor ren-
ders it potentially exploitable
therapeutically. With this in
mind, the authors show that
a recombinant EPHA7 ecto-560 Cancer Cell 20, November 15, 2011 ª2011 Elsevier Inc.domain protein (EPHA7FC)
inhibits EPHA2 phosphoryla-
tion, reduces ERK signaling
and inhibits cell growth
in vitro and can induce strik-
ing responses after intratu-
moral injection into human
lymphoma xenografts in
mice. Furthermore, an anti-
CD20-EPHA7FC fusion pro-
tein generated to target
tumor cells was able to bind
CD20 on the surface of B
cells, inhibit EPHA2 signaling
and induce apoptosis of
lymphoma cells after intra-
venous administration (Fig-
ure 1C). Not only was the
fusion protein superior to
anti-CD20 antibody treat-
ment alone, with the ability
to induce complete re-
sponses in xenografts, but
there was also no significant
short-term toxicity.
This important study raises
some questions that will re-
quire further investigation.
First, does EPHA7TR act ex-
clusively through EPHA2 or
can it also bind to other
receptors? Second, are there
other tumor suppressor
genes in the 6q region be-
sides TNFAIP3 and EPHA7,
and will combined silencing
of TNFAIP3 and possibly
other proteins encoded by
genes in this region coop-
erate with the loss of
EPHA7TR expression? Given
that 6q deletions occur in
other B cell malignancies,
such as B cell acute lympho-
blastic leukemia and diffuse
large B cell lymphoma, could
this therapeutic approach be
applicable to other B lym-
phoid malignancies? Further-
more, might these findings
extend to colon, prostate,
and gastric cancer, where
EPHA7 is also known to be
silenced, or to lung cancers
harboring EPHA7 mutations
or to breast and ovarian
cancers that have genomic
gains of EPHA2 (Pasquale,
2010)? While most tumor
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Previewssuppressors in cancer are not readily
amenable to therapeutic intervention, the
intriguing role of EPHA7TR as a secreted
tumor suppressor opens many new
avenues of investigation, including routes
with promising therapeutic applications.
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